News

The Takeda Oncology Company and the parent company, Takeda Pharmaceutical have jointly announced that Seattle Genetics and Millennium have entered into an agreement to develop and commercialise Brentuximab

AstraZeneca and the University of Virginia (UVa) have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD), with a

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has expanded its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the US. The trial,

Addex Pharmaceuticals has decided to end prematurely the migraine prevention study 206. Reportedly, the routine safety monitoring of blinded data in study 206, has revealed an incidence of

Repligen has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich’s ataxia from the Muscular Dystrophy Association (MDA). The company said that

Genocea Biosciences (Genocea) has received a grant from the University of Pittsburgh Medical Center’s (UPMC) sexually transmitted infections (STI) cooperative research center for the development of vaccines for

Ablynx has initiated a double-blind, randomised, placebo-controlled Phase I study with ALX-0141, a nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in healthy postmenopausal women.

Dr. Reddy’s has signed a Memorandum of Understanding (MoU) with the state of Louisiana on 7th December 2009, to expand its Shreveport operations with incentives and support from

Celgene has presented clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of Apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). The study was a 352-patient,